Jazz Pharmaceuticals (JAZZ) EBITDA Margin (2010 - 2026)
Jazz Pharmaceuticals' (JAZZ) quarterly EBITDA Margin came in at 31.49% in Q1 2026, up 3772.0% year-on-year from 0.81% in Q1 2025, and up 48.2% quarter-over-quarter from 21.25% in Q4 2025.
Jazz Pharmaceuticals (JAZZ) EBITDA Margin (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' EBITDA Margin history runs 17 years deep, the most recent figure standing at 31.49% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 3772.0% year-over-year to 31.49% in Q1 2026; TTM through Mar 2026 was 0.85%, a 1548.0% decrease from a year earlier, with the FY2025 full-year figure at 10.08%, down 2769.0% from the prior year.
- EBITDA Margin rose to 31.49% in Q1 2026 per JAZZ's latest filing, from 21.25% in the prior quarter.
- Across five years, EBITDA Margin topped out at 31.49% in Q1 2026 and bottomed at 65.64% in Q2 2025.
- The 5-year median for EBITDA Margin is 12.11% (2023), against an average of 6.52%.
- Across the five-year window, EBITDA Margin soared 3920 bps in 2023 and sank 8512 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 27.09% in 2022, then surged by 145 bps to 12.11% in 2023, then surged by 45 bps to 17.53% in 2024, then increased by 21 bps to 21.25% in 2025, then surged by 48 bps to 31.49% in 2026.
- Per Business Quant, the three latest JAZZ EBITDA Margin figures stand at 31.49% (Q1 2026), 21.25% (Q4 2025), and 5.11% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Jazz Pharmaceuticals | 15.78 Bn | 13.93 Bn | 934.80 Mn | 31.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.49% |
| Dec 31, 2025 | 21.25% |
| Sep 30, 2025 | 5.11% |
| Jun 30, 2025 | -65.64% |
| Mar 31, 2025 | -6.23% |
| Dec 31, 2024 | 17.53% |
| Sep 30, 2024 | 24.67% |
| Jun 30, 2024 | 19.48% |
| Mar 31, 2024 | 7.34% |
| Dec 31, 2023 | 12.11% |
| Sep 30, 2023 | 17.73% |
| Jun 30, 2023 | 16.47% |
| Mar 31, 2023 | 14.12% |
| Dec 31, 2022 | -27.09% |
| Sep 30, 2022 | 2.63% |
| Jun 30, 2022 | 9.17% |
| Mar 31, 2022 | 10.76% |
| Dec 31, 2021 | 5.51% |
| Sep 30, 2021 | 3.38% |
| Jun 30, 2021 | -9.26% |